GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026Business Wire · 2 days ago
GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease DiagnosisBusiness Wire · 5 days ago
GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026Business Wire · 6 days ago
GeneDx (NASDAQ:WGS) Stock Falls 5.5% – Here’s What HappenedDefense World · Oct 18, 2026
Analyzing GeneDx (NASDAQ:WGS) and LifeMD (NASDAQ:LFMD)Defense World · Oct 18, 2026
Comparing GeneDx (NASDAQ:WGS) & Brookdale Senior Living (NYSE:BKD)Defense World · Oct 10, 2026GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 3, 2026 | -$0.19 | $0.01 | Beat |
| May 4, 2026 | -$0.06 | -$0.28 | Miss |
| Feb 23, 2026 | $0.11 | $0.14 | Beat |
| Oct 28, 2025 | $0.28 | $0.49 | Beat |
| Jul 29, 2025 | $0.10 | $0.50 | Beat |
| Apr 30, 2025 | $0.11 | $0.28 | Beat |